CollPlant enters the wound-healing market in Israel: Treatments using the wound-healing product have started in a large clinic in the center of the country
Commercial treatments in several European countries have demonstrated excellent results for healing chronic wounds.
Ness Ziona, Israel, July 17, 2017, CollPlant Ltd. (TASE: CLPT), a regenerative medicine company utilizing its proprietary plant-based rhCollagen technology for tissue repair products (recombinant human, “rhCollagen”), announced that it has started treatments of acute and chronic wounds using Vergenix®FG. Yesterday, over ten patients with different types of hard-to-heal chronic wounds were treated for the first time in Israel, by a large private wound-treatment center in the Tel Aviv metropolitan area. The product is administered in Israel following approval of the Medical Device and Accessories Department of Israel’s Ministry of Health, which was received last month. To expand the use of the product, the Company is acting to receive indemnity from the Israeli Ministry of Health.
Over the past year, CollPlant started commercial use of the product in several European countries, and post marketing surveillance (PMS) of dozens of patients demonstrate excellent healing results.
Yehiel Tal, CEO of CollPlant: “We are pleased to offer treatments using our product in Israel, following high satisfaction with the results of treatments in Europe, which consistently demonstrate product effectiveness. We are taking steps to expand our operations in Europe, with the aim of continuing to establish VergenixFG as an innovative and leading product for advanced wound healing”.
CollPlant is a regenerative medicine company leveraging its proprietary, plant-based recombinant human collagen (rhCollagen) technology for the development and commercialization of tissue repair products, initially for the orthobiologics, 3D Bio-printing of tissue and organs, and advanced wound care markets. The Company’s cutting-edge technology is designed to generate and process proprietary rhCollagen, among other patent-protected recombinant proteins. Given that CollPlant’s rhCollagen is identical to the type I collagen produced by the human body, it offers significant advantages compared to currently marketed tissue-derived collagen, including improved biofunctionality, superior homogeneity and reduced risk of immune response. The Company’s broad development pipeline includes biomaterials indicated for orthopedics and advanced wound healing. Lead products include: Vergenix®STR (Soft Tissue Repair Matrix), for the treatment of tendinopathy; and Vergenix®FG (Flowable Gel) wound filler, for treatment of acute and chronic wounds. CollPlant’s business strategy includes proprietary development and manufacture of tissue repair products and their commercialization and distribution, together with leading third parties, alongside alliances with leading companies for joint development, manufacture and marketing of additional products.
For more information about CollPlant, visit http://www.collplant.com